Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -1.61 | $0 | -$3M |
| 2025 Q4 | -1.20 | $0 | -$2M |
| 2025 Q3 | -1.50 | $0 | -$4M |
| 2025 Q2 | -1.53 | $0 | -$3M |
| 2025 Q1 | -3.25 | $0 | -$3M |
| 2024 Q4 | -2.60 | $0 | -$3M |
| 2024 Q3 |
| -1.74 |
| $0 |
| -$4M |
| 2024 Q2 | -1.97 | $0 | -$3M |